Dr. Pishvaian on the Implications of the RATIONALE-306 Trial in ESCC
January 25th 2023Michael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.
Read More